Povetacicept
Sponsors
Alpine Immune Sciences, Inc., Alpine Immune Sciences Inc, A Subsidiary of Vertex, Vertex Pharmaceuticals Incorporated
Conditions
Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisCold Agglutinin DiseaseHealthy VolunteersIdiopathic Thrombocytopenic PurpuraImmune ThrombocytopeniaImmunoglobulin A NephropathyLupus NephritisMembranous Nephropathy
Phase 1
An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases
Active, not recruitingNCT05732402
Start: 2023-03-15End: 2028-03-02Updated: 2025-10-14
An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias (RUBY-4)
CompletedNCT05757570
Start: 2023-07-03End: 2026-08-12Updated: 2026-09-14
A Study to Evaluate the Relative Bioavailability of Povetacicept Formulations and Bioequivalence of Povetacicept Presentations
CompletedNCT07010406
Start: 2025-06-06End: 2025-08-19Updated: 2025-09-18
Phase 2
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
RecruitingNCT07204275
Start: 2025-09-30End: 2028-12-29Target: 176Updated: 2026-09-18
A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis
RecruitingNCT07501702
Start: 2026-05-13End: 2029-03-02Target: 30Updated: 2026-09-11
Phase 3
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
Active, not recruitingNCT06564142
Start: 2024-08-30End: 2028-01-30Updated: 2026-05-15
A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A Nephropathy
Not yet recruitingNCT07807995
Start: 2026-09-18End: 2029-12-28Target: 605Updated: 2026-09-08